LTRN FY 2024 Earnings — Lantern Pharma Inc. Revenue & Financial Results | Market Cap Arena

LTRNLantern Pharma Inc.

$31M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$22M

Net Income

-$21M

EPS (Diluted)

$-1930.92

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$26M

Total Liabilities

$4M

Stockholders' Equity

$21M

Cash & Equivalents

$8M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$174,843	+100.0%
Operating Income	-$22M	-$18M	-24.3%
Net Income	-$21M	-$16M	-30.2%